Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Recommendation of “Moderate Buy” from Analysts

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has been assigned a consensus rating of “Moderate Buy” from the ten research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $17.80.

Several research firms have recently commented on EPRX. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Wedbush assumed coverage on Eupraxia Pharmaceuticals in a report on Thursday. They set an “outperform” rating and a $17.00 price objective for the company. Wall Street Zen raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 12th. Stifel Nicolaus set a $25.00 target price on Eupraxia Pharmaceuticals in a research note on Thursday. Finally, Oppenheimer initiated coverage on Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They issued an “outperform” rating and a $17.00 target price on the stock.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Several large investors have recently made changes to their positions in EPRX. Affinity Asset Advisors LLC increased its holdings in Eupraxia Pharmaceuticals by 429.7% in the first quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after buying an additional 1,289,005 shares during the last quarter. Jupiter Topco LLC acquired a new stake in Eupraxia Pharmaceuticals in the second quarter valued at approximately $6,851,000. Seven Fleet Capital Management LP acquired a new stake in Eupraxia Pharmaceuticals in the first quarter valued at approximately $5,137,000. Redmile Group LLC bought a new stake in Eupraxia Pharmaceuticals in the first quarter worth approximately $5,068,000. Finally, Rubric Capital Management LP bought a new stake in Eupraxia Pharmaceuticals in the first quarter worth approximately $5,004,000.

Eupraxia Pharmaceuticals Stock Performance

EPRX stock opened at $8.01 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.00 and a current ratio of 16.00. The stock has a market cap of $520.81 million, a P/E ratio of -7.85 and a beta of 1.07. The firm has a 50 day simple moving average of $7.18 and a 200 day simple moving average of $7.01. Eupraxia Pharmaceuticals has a 52 week low of $5.25 and a 52 week high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. Research analysts anticipate that Eupraxia Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX) is a clinical-stage biotechnology company based in Canada. The company develops locally administered therapies intended to treat inflammatory, fibrotic and other diseases while limiting patients’ exposure to medication throughout the body.

Eupraxia’s development programs are built around its proprietary Diffusion Driven Drug Delivery (3D) platform. The technology is designed to provide controlled, sustained release of pharmaceutical compounds at targeted sites, potentially extending treatment effects and reducing systemic side effects.

The company’s lead product candidate, EP-104I, is an extended-release formulation of fluticasone propionate being developed for intra-articular administration in patients with osteoarthritis of the knee.